APOE polymorphism is associated with blood lipid and serum uric acid metabolism in hypertension or coronary heart disease in a Chinese population.

To explore the association of APOE polymorphism (rs7412:526C>T and rs429358:388T>C) with glucose, lipid and serum uric acid (UA) metabolism in patients with hypertension or coronary heart disease (CHD). A total of 544 patients with hypertension or CHD were selected for this study from March 2017 to January 2018. According to the genotypes (excluding the E2/E4 genotype), the subjects were divided into three groups (E2/E2+E2/E3 genotypes, E3/E3 genotype [the wild-type] and E3/E4+E4/E4 genotypes) and the difference of metabolism among the three groups was compared. There were significant differences in total cholesterol (TC), triglycerides, low-density lipoprotein (LDL), high-density lipoprotein and serum UA levels among the three groups. Compared with E3 homozygote, E4 carriers possessed higher TC, triglycerides and LDL levels, whereas E2 carriers had higher high-density lipoprotein level, lower TC and LDL levels. Furthermore, multivariate logistic regression analysis found that setting E3/E3 genotype as the reference group, the carriers of E4 allele (E3/E4+E4/E4 genotypes) were significantly related to hypertriglyceridemia, and E2 allele (E2/E2+E2/E3 genotypes) was significantly correlated with hyperuricemia. polymorphism was associated with blood lipid and serum UA metabolism in patients with hypertension or CHD. Compared with E3 homozygote, E4 allele was related to elevated triglycerides, and E2 allele was correlated with increased serum UA level.